Celldex (TCE1) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Celldex CH:TCE1 is currently developing the following drugs: Standard Of Care, Barzolvolimab, Barzolvolimab, Cdx-622, Normal Saline, Cdx-622, Cdx-585, Cdx-1140, Odetiglucan, Normal Saline, Cdx-0159, Cdx-0159, Cdx-527, Pembrolizumab, Cdx-301, Chemotherapy, Cdx-1140, Cdx-3379 And Cetuximab, Cdx-014, Cdx-0158, Combination Of Varlilumab And Atezolizumab, Ktn3379, Ktn3379, Vemurafenib, Combination Of Varlilumab And Ipilimumab, Cohort A: Varlilumab & Ipilimumab; Cohort B: Varlilumab, Ipilimumab, Cdx-1401 & Poly-Iclc, Combination Of Varlilumab And Sunitinib, Combination Of Varlilumab And Nivolumab, Glembatumumab Vedotin, Glembatumumab Vedotin And Varlilumab, Glembatumumab Vedotin And Pd-1 Targeted Checkpoint Inhibitor, Glembatumumab Vedotin And Cdx-301, Ont-10, Varlilumab Combination, Cdx-301, Cdx-301 And Plerixafor, Capecitabine, Cdx-011, Bevacizumab, Rindopepimut With Gm-Csf, Klh, Temozolomide, Rindopepimut With Gm-Csf, Klh, Cdx-301, Cdx-1127, Cdx-011, "Investigator's Choice" Chemotherapy, Chemotherapy, Cdx-1307 Vaccine Regimen. These drug candidates are in various stages of clinical development as the company works toward FDA approval.